Market Overview

UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk

Share:
Related KERX
56 Biggest Movers From Yesterday
45 Stocks Moving In Tuesday's Mid-Day Session
Keryx: The Solution Is The Problem (Seeking Alpha)

In a report published Monday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), but lowered the price target from $27.00 to $21.00.

In the report, MLV & Co noted, “KERX reported 1Q results last week, but the main focus was mgmt's comments on the call surrounding outstanding CMC issues with the NDA for lead asset Zerenex (hyperphosphatemia). We hadn't previously been aware of CMC issues, and while KERX has provided add'l data on this (as well as drug-drug interactions, with info on both recently requested by FDA), we were disappointed to hear of this latest update. With the Zerenex PDUFA just one month away (June 7) and mgmt on multiple occasions citing ‘there are no guarantees' (yes, we applaud the transparency), we're feeling a bit less confident in an on-time approval.

"We don't model a delay for Zerenex at this time, but given the increased risk in a potential on-time FDA approval, we now increase the discount rate in our DCF from 17.5% to 20%, and as a result, lower our 1-yr PT to $21 (vs. prior $27, but still 73% upside).”

Keryx Biopharmaceuticals closed on Friday at $12.11.

Latest Ratings for KERX

DateFirmActionFromTo
Nov 2017Stifel NicolausMaintainsHold
Jul 2017Morgan StanleyMaintainsEqual-Weight
Jan 2017CitigroupUpgradesSellNeutral

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

Posted-In: Graig C. Suvannavejh MLV & CoAnalyst Color Price Target Analyst Ratings

 

Related Articles (KERX)

View Comments and Join the Discussion!

Partner Center